DT Midstream's Q3 Adjusted Earnings Miss Analysts' Estimates; Maintains Quarterly Dividend-March 2024-www.financetom.com

DT Midstream's Q3 Adjusted Earnings Miss Analysts' Estimates; Maintains Quarterly Dividend

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

DT Midstream's Q3 Adjusted Earnings Miss Analysts' Estimates; Maintains Quarterly Dividend

Nov 3, 2024 1:37 PM

07:58 AM EDT, 10/29/2024 (MT Newswires) -- DT Midstream ( DTM ) reported Q3 adjusted earnings Tuesday of $0.90 per diluted share.

Analysts surveyed by Capital IQ expected $0.96.

The company maintained its quarterly dividend at $0.735 per share, payable Jan. 15 to shareholders of record Dec. 16.

Price: 87.34, Change: -0.08, Percent Change: -0.09

Previous page： BlackBerry's Valuation to Remain Discounted on 'Conservative' Guidance, RBC Says Next page： Google agrees $36 million fine for anti-competitive deals with Australia telcos

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BlackBerry's Valuation to Remain Discounted on 'Conservative' Guidance, RBC Says

Jun 20, 2025

09:16 AM EDT, 06/20/2025 (MT Newswires) -- BlackBerry's (BB) conservative guidance has set the bar low for fiscal Q1 earnings and the company's valuation is likely to remain discounted, pending improved visibility to sustained growth, RBC Capital Markets said in a Friday note. The company's fiscal Q1 results could exceed RBC's and consensus estimates, as the macro environment has been...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial

Jun 20, 2025

09:17 AM EDT, 06/20/2025 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers. The analysis identified seven biomarkers as uniquely significant predictors of favorable survival...

Update: Lilly to Appeal Against UK Regulator's Recommendation Not to Reimburse Cost of Alzheimer's Drug

Jun 20, 2025

09:26 AM EDT, 06/20/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday it was planning to appeal against the UK's National Institute for Health and Care Excellence's, or NICE's, decision not to reimburse the cost of Alzheimer's drug Kisunla under the National Health Service. The drugmaker said the regulator's decision is unreasonable based on the evidence submitted by...